Comerica Bank raised its position in United Therapeutics Corporation (NASDAQ:UTHR) by 1.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 35,249 shares of the biotechnology company’s stock after buying an additional 458 shares during the period. Comerica Bank owned approximately 0.08% of United Therapeutics Corporation worth $4,635,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in UTHR. Capstone Asset Management Co. raised its position in United Therapeutics Corporation by 5.8% in the first quarter. Capstone Asset Management Co. now owns 5,723 shares of the biotechnology company’s stock worth $775,000 after buying an additional 316 shares during the period. Retirement Systems of Alabama raised its position in United Therapeutics Corporation by 4.1% in the first quarter. Retirement Systems of Alabama now owns 83,247 shares of the biotechnology company’s stock worth $11,270,000 after buying an additional 3,274 shares during the period. Nationwide Fund Advisors raised its position in United Therapeutics Corporation by 5.6% in the first quarter. Nationwide Fund Advisors now owns 109,868 shares of the biotechnology company’s stock worth $14,874,000 after buying an additional 5,789 shares during the period. Korea Investment CORP raised its position in United Therapeutics Corporation by 1.6% in the first quarter. Korea Investment CORP now owns 97,700 shares of the biotechnology company’s stock worth $13,227,000 after buying an additional 1,500 shares during the period. Finally, DUPONT CAPITAL MANAGEMENT Corp raised its position in United Therapeutics Corporation by 10.2% in the first quarter. DUPONT CAPITAL MANAGEMENT Corp now owns 18,800 shares of the biotechnology company’s stock worth $2,545,000 after buying an additional 1,737 shares during the period.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) opened at 128.45 on Friday. The stock has a market capitalization of $5.58 billion, a P/E ratio of 14.90 and a beta of 1.51. United Therapeutics Corporation has a 12 month low of $110.90 and a 12 month high of $169.89. The firm’s 50-day moving average price is $130.18 and its 200-day moving average price is $133.12.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $3.61 by $4.86. The company had revenue of $444.60 million during the quarter, compared to analysts’ expectations of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period last year, the business posted $4.42 earnings per share. On average, equities research analysts forecast that United Therapeutics Corporation will post $10.09 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://theolympiareport.com/2017/08/27/united-therapeutics-corporation-uthr-stake-raised-by-comerica-bank.html.

A number of equities analysts have recently weighed in on UTHR shares. ValuEngine lowered United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 2nd. Jefferies Group LLC reiterated a “sell” rating and issued a $105.00 target price on shares of United Therapeutics Corporation in a research report on Thursday, June 8th. BidaskClub upgraded United Therapeutics Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, June 9th. UBS AG reiterated a “sell” rating and issued a $106.00 target price on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Finally, Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. Six analysts have rated the stock with a sell rating, six have assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $134.50.

In other news, Director Richard Giltner sold 3,490 shares of the stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $131.12, for a total value of $457,608.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 1,251 shares of the stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $125.02, for a total transaction of $156,400.02. Following the completion of the sale, the chief executive officer now owns 1,391 shares in the company, valued at $173,902.82. The disclosure for this sale can be found here. Insiders sold 24,622 shares of company stock worth $3,203,127 over the last quarter. Company insiders own 7.80% of the company’s stock.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.